Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Canatu, Webcast, Q2'25

By Inderes8/29/2025, 9:00 AM
Canatu

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Marie Makkonen
00:00 - 00:37

My name is Marie Makkonen and I'm responsible for Investor Relations. Today, our CEO, Juha Kokkonen, will start with the first half highlights. Then our CFO, Mikko Vesterinen, will continue with the key financials. And after that, our business unit lead Nedal Safwat will provide an update on medical diagnostics. Finally, Juha will discuss outlook and targets at the end. We'll have plenty of time for Q&A. You can type in your questions in the chat at any time. With that, let me hand over to Juha.

Juha Kokkonen
00:42 - 12:06

Thank you, Marie, and welcome also on my behalf. I will go straight to the key messages we are envisioning here, seeing very rapid growth in artificial intelligence. This is driving a demand for advanced chips, both in terms of volume and performance. In terms of performance, it's also necessary to make these language models faster, more cost-efficient, and less energy-consuming. This development is a main driver for advanced chips that are continually becoming more advanced, and this also drives the demand for CNT pellicles. And CNT pellicles are a small yet essential part of this development from an operational progress perspective. The major milestone during the first half of this year was that our first reactor was customer approved, and it is now ready for mass production of CNT pellicle membranes. In addition to that, while negotiating new orders in the semiconductor industry with our existing customers, as you may remember, we have two reactor customers there. In addition to that, we have one prospective new customer, and we have a project going on there as well. And this will ensure that our position within the existing ecosystem remains strong; in fact, we can even say that it has improved compared to the time of the listing. Our first half result was a disappointment to me. So, our revenue was 7.3 million and that was down by 34%. So our revenue was 7.3 million, and that was down by 34%. This was caused by three main reasons. The first reason is that the semiconductor industry has delays in adopting these high-power scanners. Secondly, in addition, from the Canatu Plc side, there has been slower than anticipated customer approvals. And thirdly, we do see there are certain general market uncertainties that are related to tariffs. Also, whether AI chips can be sold to China or not, or whether they have tariffs or not. However, we are investing heavily in future growth as well as diversification. We are doubling our premises with a new factory and enabling further growth. Secondly, we have made a strategic long-term commitment to medical diagnostics, and today you will hear from Nedal Safwat, who is our new business leader, providing more insights into our strategy in this domain. Also, we are fostering new business development aiming for a faster time to market of high-value applications. And as you may remember, most of our applications that we are selling today actually have their inputs coming from the customers. And therefore, now we are establishing a team who can really handle those, understand the business opportunities, and provide faster time to market for those new application domains. So as a top-line message, despite the delayed revenue, we have a competitive position in CNT pellicles, and that has remained very strong. And I would say that it has even improved. And the second key message here is that we are accelerating our investments in future growth. Secondly, I will look at some key drivers in this advanced chip business. These advanced chips, also known as EUV chips, at seven nanometer and below nodes are the fastest growing segment in the semiconductor industry. The semiconductor industry in general is growing at around 10% annually, forecasted to be $1,000 billion by 2030, and advanced chips are growing at double that rate in size. Now, in this roadmap, as you see in this picture, you can observe the development of the ASML scanners to 500 watts, moving to 600 watts, and further, demonstrating how these nodes related to that are developed as well. From Canatu's perspective, the most important development here is that we anticipate, and industry sources especially anticipate, that advanced chip manufacturing with 600-watt power scanners will start by 2027, and this is expected to be the inflection point for wider usage of CNT pellicles. However, based on the work we have already done, we expect there will be CNT pellicles usage with Y100 scanners. What scanners. The main reason for this is what we have communicated earlier, which is that CNT pellicles provide higher transmission and therefore productivity gains. Some highlights of our first half progress include what we have discussed extensively: the first reactor, which is now ready for pellicle membrane mass production. Before pilot and risk production. The first customer we have must still secure approval for the complete quoted CNT pellicles product. After this is successfully done. As you remember from our business model perspective, Canatu Plc will start generating revenue not only from the reactors, but also from consumables and sold CNT pellicles. We looked at this picture also during our last year's results. And what you can see here is the progress with the first customer that has moved from the customer approval process, which has been completed, and they are right now in the process of getting the approval for the full CNT pellicles product. The second customer has also been moving from the delivery assembly phase to the customer approval phase, so the point of these reactor deliveries has made significant progress on top of this one. What I already mentioned earlier is that we have ongoing negotiations for new reactor sales, both with our two existing reactor customers, and there has also been significant progress with new customers. We have a project going on there, and this is why we anticipate an improved market position in the CNT pellicles domain. We are also investing heavily in new business development, conducting systematic assessments of new high-value applications. So we are accelerating with enhanced resources and a dedicated team, aiming for a faster time to market for high-value applications. This is like the key element when you think about it. If you think about Canatu Plc. We are delivering the most advanced CNT pellicles, and in this way, we can address not only the current business domains but also future business domains. Some of the key examples. What we already communicated during the first half. And I start from the right-hand side with this defense industry solution, where we began mass production of sensors protecting advanced electronic devices in the defense industry. This is an example where we are utilizing our existing capabilities and processes. This product is similar to touch sensors, providing us the opportunity to bring new solutions to the market in a reasonably short period of time. Then another type of example is the next generation solar panels, applications where we are targeting to achieve with the new innovative stack involving CNT electrodes, almost 40% efficiency increase for solar panels, so achieving up to 35% efficiency there. So this is another example where we're seeing that the development time will be longer, and we expect that the revenue here will occur after 2027. And now I'm referring to mass production revenue. We have been communicating about the significant development revenue expected to be recognized this year. And now I would like to hand over to Mikko to cover our financial results.

Mikko Vesterinen
12:13 - 16:10

And I start from the right-hand side with this defense industry solution where we began mass production of sensors protecting advanced electronic devices in the defense industry. And I start from the right-hand side with this defense industry solution where we began mass production of sensors protecting advanced electronic devices in the defense industry. Like you said, the financial performance in the first half was disappointing. Uh, operationally, the progress was good. And like I said, we see our position as very good. The revenue amounted to €7.3 million, which implied approximately a one-third decline compared to the same period a year ago. And a gross profit amounted to 4.9 million. And the gross margin improved to 67.3%. The key drivers behind this revenue development, or the first half revenue, were a good performance in the inspection membrane business. Uh, the final, uh, revenue recognition of this first, uh, CNT100 SEMI reactor project and then, um, uh, the new, uh, joint development program in the automotive business area with Denso, uh, with regards to the margin development said the gross margin improved compared to the first half of '24, and that was driven by the changes in the product mix. A year ago, the first half revenue was largely influenced by the revenue recognition of the first two reactor projects. And as you remember, we explained in connection with the full year results that as these are the first two projects, there have been many things which we and our customers have learned during the process, and therefore they have had a somewhat lower margin than what we expect going forward. Uh, adjusted EBIT, which is the key earnings metric that we are following in the long term, declined, obviously, as well, driven by the decline in the revenues. And also, we've been investing in future growth, and the headcount has been growing. As we've been recruiting more people to the teams. Then if we look at the split between the business segments, uh, our revenue from semiconductors continues to be the main revenue source for us. And the drivers there, as just explained, were the good performance in the inspection membrane business and this first reactor being now fully finalized. Uh, so 5.7 million of the revenue came from semiconductors, and 1.6 million came from automotive. And there the key contributor was this new project with Denso. But that's in line with what we've been communicating earlier. It's in the development phase. But we see that there's a good long-term value creation potential, and it's one of our key strategic growth areas going forward. These were the main messages. Happy to answer them in the Q&A for any questions you may have.

Juha Kokkonen
16:13 - 16:47

Thank you. Michael. I would like to invite Nedal Safwat to the floor next. And Neil has been running really significant portfolios on this medical diagnostics side, with sizes ranging between half a billion and 3 billion. And we are very excited that you joined our company. Maybe I'm asking you what inspired you to join Canatu Plc and what potential do you see here?

Nedal Safwat
16:48 - 23:08

Thank you and good afternoon, everyone, and thank you for giving me the opportunity to present on the medical diagnostic business unit progress. Uh, as you mentioned, I've been in the medical diagnostic field for quite some time, over 25 years, with a strong passion for taking technologies and enabling progress in development and commercialization. I've guided several product portfolios from early concept development all the way to commercialization. I've also had the privilege of leading different functions within the top large diagnostic companies in the industry, and across these roles, I saw the emerging field in medical diagnostics and how there's an emerging and evolving need in point-of-care diagnostics. Medical diagnostics is really evolving to bring results closer to the patients, allowing faster results and improving patient treatment. And this is why Canatu Plc's carbon nanotube potential in medical diagnostics could not go unnoticed. It was very obvious that after assessing numerous technologies, I see the potential that technology has, and really the unique differentiation and potential lie in the technology's exceptional sensitivity, versatility to detect different types of targets, and the mass production capability that's already in place, which is very exciting to see. So the opportunity to lead this journey with a revolutionary technology and applying my experience to enhance patient care is really why I'm here today. So I want to share with you just real quick the point of care diagnostics market, what it is and how it's evolving. In summary, point-of-care diagnostics refers to medical testing that's performed near or at the point of patient care, meaning the results or tests occur close to the patient in a short period of time, enabling faster clinical decisions. This has had a significant impact on patient care by driving better clinical outcomes, faster time to results, and improving the ability to triage patients into the hospital and healthcare system for timely interventions. Not to mention, we've also witnessed the impact of point-of-care testing on public health surveillance and the response we saw during the pandemic, which had a significant impact on our healthcare system. Point of care diagnostics has also seen significant adoption because it helps improve the economic aspect or the health economics of testing within a healthcare system. Simple tests are easier, provide faster time to results, and prevent the need for expensive lab equipment at centralized labs. So, our approach or our strategy is really simple. We looked at the technology that we have. We also conducted a market study to assess how our technology fits in the market. And while the potential is quite vast, there are different applications for point-of-care. Uh, and the market continues to evolve at a rapid rate. Infectious disease. Hormone monitoring was one of the two key areas that were very clear and identified as having strong potential for us to enable our technology to provide key advantages there. If we look at the health sector, the global market is about 6 billion, with the US market comprising over 50% of that. We see the demand. We see the evolving need and the key drivers that are pushing the point of care diagnostics. So, uh, we looked at how we can ensure that we have a solid roadmap that's straightforward and focused. And first, we evolved our hormone monitoring therapy as a proof of concept to build and show that our technology works for detecting hormone levels at the biological level. Second, we also have an infectious disease area that is in desperate need of development, and we are working on building a test for it. And third, we're accelerating our progress through strategic partnerships in both the public and private sectors. Uh, and I'm excited to share with you today two key, uh, publications that show the progress of the technology and demonstrate that the technology is evolving quite fast. The first is for detecting circulating tumor DNA. And circulating tumor DNA is basically tiny fragments that shed in the blood as an early indicator of cancer. And we were able to show with our electrochemical biosensor that we were able to pick up circulating tumor DNA at a very low level, demonstrating the sensitivity and specificity of our electrochemical biosensors. The second study focused on testosterone detection. And we were able to show that we can detect very low levels of testosterone at the same biological level typically tested in a central lab. Again, this provides significant progress for the technology and shows that we have strong potential to move forward in point-of-care settings. This is an exciting journey, and the progress that we've made is incredible, promising, and confirms that we're on the right track. We've identified a clear market need. We have a versatile, powerful, and sensitive technology that enables us to transform patient care in the point-of-care setting. Thank you for your attention and back to you.

Juha Kokkonen
23:11 - 30:45

So, uh, we looked at how we can make sure that we have a solid roadmap that's straightforward and focused. Netherlands. Thank you for joining. Joining Canatu Plc. I will next cover outlook and targets. So first, when we look at the 2025 outlook, So, Canatu Plc expects that our full-year revenue will decline compared to our last year's revenue of €22 million. If there are no new CNT100 SEMI reactor orders received during the second half of the year. We can expect a decline that is significant compared to the 2022 revenue. In the near term, we see certain key factors that are affecting the revenue visibility and may increase the volatility of our revenue. There are mainly two elements to that one. The number one is related to our first customer's rollout of the CNT pellicles and the timing of that rollout. And the second one is related to our second reactor customer's approval timing. And then as those are not fully in control of Canatu Plc, we are not providing any numeric guidance for the rest of the year. Then, however, when we look at the long-term financial targets. So as I mentioned earlier, we do see delayed revenue. But we do believe and see that our competitive position is very strong and has even improved. So therefore, we are keeping our financial targets for 2027, which are a revenue of 100 million and an EBIT margin over 30%. However, the uncertainty concerning the timeline for achieving the long-term financial targets has materially increased. And this is the main reason for this. One reason is the semiconductor industry's delay in adopting high power scanners, which affects achieving the 100 million revenue target. We see that the following assumptions are highly important. Firstly, from the semiconductor side, which is the largest contributor to revenue. It requires that Canatu Plc's position in CNT pellicles as well as in inspection membranes remains strong. Secondly, what we have been already talking about here quite a lot is that ASML's high power scanner deployment is scheduled to start by 2027, so that there will be volume generated for both 2027 and 2028. The second key point from the automotive side is that in addition to the camera heater mass production, But we have started. We will see ADAS camera heaters in mass production with our lead customers. And thirdly, uh, Nedal covered this new medical strategy and the kind of initial roadmaps there. The proof of concepts we are developing are in progress and will start generating development revenues. We have now started the process of a strategic assessment where we are closely monitoring what is happening in the marketplace as part of this annual strategy process. After that, when we have made decisions, there are some very exciting opportunities to be explored based on the new opportunities we will provide. Update on this topic to the longer-term targets in our next Annual Capital Markets Day that is scheduled to be held in March 2026. Then, getting back to the key messages. There is a very rapid growth in artificial intelligence that is driving high demand for advanced technologies. Chips that are becoming increasingly capable. CNT pellicles are expected, and I believe strongly that they are a key part of enabling future advanced chips. Canatu's position for those advanced chips in terms of delivering CNT pellicles, reactors, and membranes is very strong and has been improving based on the progress since its listing last year. We are investing for growth as well as further portfolio diversification. So firstly, we are doubling our premises with a new facility. We have made a strategic long-term commitment to medical diagnostics. We have also made commitments to create this new business development team. As you know, we are receiving a significant number of new business proposals. This team will accelerate our development and the time to market for these new high-value applications. And we showed a couple of examples there. So as a top line message, what I would like to conclude and end with is here. Canatu's competitive edge in CNT pellicles has remained strong and improved. We are accelerating further growth in future business areas. Thank you very much.

Marie Makkonen
30:51 - 30:59

And now it's time for questions. Let's begin with questions from the audience here at San Bartolo. Walter, please go ahead.

Walter Rossi
31:00 - 31:24

Hi. Thank you. Thank you for the presentation. Walter Rossi from Danske Bank. Uh, I'll first start with some questions related to the market. You mentioned many times that your competitive position has even improved during H1. Um, can you kind of back up that claim? Uh, why do you think that way so strongly?

Juha Kokkonen
31:25 - 32:19

The reason there is that we have made progress with our two existing customers. Secondly, in addition to those two customers, there is significant demand from other players in the industry to get Canatu Plc's CNT pellicle membrane technology, so they can also provide CNT pellicle solutions to the marketplace. So that's like the key reason, and you may ask, have we continued that one? Have we lost any deals there? No, we haven't. So it's basically that the situation is actually improving as we are gaining a new, even stronger position here.

Walter Rossi
32:22 - 32:52

All right. So in high as a top line message, what I would like to conclude and end here. Based on your best knowledge, do you think that everyone who is testing or already using high NA EUV machines uses CNT pellicles with them? Or do you know if there are alternative ways to address the same problems or issues with the machine? And, uh, what are they?

Juha Kokkonen
32:52 - 33:40

Okay, first of all, it is very important to understand that CNT pellicles are equally important for low Na as well as for high-end equipment. So in both of these, in ASML's roadmaps, you are increasing power to 600 and further there. So it's not only a high-end game, which is very important currently, as there are very few high-end pieces of equipment installed in the marketplace. Uh, based on my knowledge, high NA equipment is not yet in mass production by any foundries.

Walter Rossi
33:43 - 34:03

But do you think that companies who have both these high-end machines and are already testing these machines, do you think that all of those have both CNT pellicles supply or another solution for that?

Juha Kokkonen
34:04 - 35:21

Yeah. The current situation in the marketplace is that the established solution is a composite solution. That is the kind of technology solution that includes metal silicide. And that's the solution that is currently used in all mass productions. What is happening in the marketplace, as we communicated here, is that we are at a situation with our first reactor customer; they have accepted our part of the delivery, and they are currently in the process of getting acceptance for the complete CNT pellicles product. So they are not yet used in full mass production with any technology. But like we said, we do believe that there will be usage with 500W scanners. And what we are saying is that we do see the industry indicating in their roadmaps that the transition inflection point will happen with 600 watt systems.

Walter Rossi
35:22 - 35:50

But, uh, do you think that, um, companies who have both these high-end machines and are already testing these machines, do you think that all of those, uh, have both CNT pellicles supply or other, um, solutions for that? Fair enough. There's been some speculation in the media that maybe Intel will split their design and manufacturing operations, and that could have an impact also on the high-end adoption in the market and in your relevant market. How do you see that potentially impacting your short and long-term outlook?

Juha Kokkonen
35:51 - 36:46

I don't want to speculate on Intel's splitting and so on, but what I can only say is that there is a similar demand and requirement by all the foundries who will go for these high-power systems, whether they are part of Intel or somehow diversified from Intel. So I think that the ownership structure does not make any changes here. And like we said, based on the existing customers we have and the new prospects, we aim to address the entire market.

Walter Rossi
36:47 - 37:22

All right. But do you think that companies who have both these high-end machines and are already testing them, do you think that all of those have both CNT pellicle supply or another solution for that? Um, a few hopefully quick ones on the revenue side of things, focusing on recurring revenues and the timeline. And can you remind us, what are we talking about here? How long will it take from the final acceptance to moving into mass production? Could you even provide a range?

Juha Kokkonen
37:24 - 38:01

I think that this is an ongoing process, and we cannot tell you how many months it will take. Right now, of course, I do know the kind of plans that are currently in progress and how they are developing. So, therefore, what we have been communicating here is that we do believe there will be CNT pellicles based on the Canatu Plc technology to be used already with these 500 watt systems and basically with two nanometer nodes.

Walter Rossi
38:04 - 38:25

But, do you think that companies who have both these high-end machines and are already testing these machines have both CNT pellicles supply or other solutions for that? Um, on the second customer, do they require the exact same approvals as the first customer before moving into production? Um, and do you expect to receive the final acceptance? Uh, there still this year.

Juha Kokkonen
38:27 - 38:27

So.

Walter Rossi
38:28 - 38:28

Sorry.

Juha Kokkonen
38:28 - 39:48

The first. Yes. Yes. Customer requirements vary significantly in this industry. You have basic recommendations and requirements that are coming from ASML. So that is more or less seen as a minimum level there. But then we may have different additional requirements coming from our customers, and the requirements are not actually exactly the same. So I do see that this pellicle development is not like this. When we get another approval for this one, the development will not stop. No, it will be as it always is in the semiconductor industry. There will be new requirements coming after this one. This is, for example, one reason why we invested in this kind of system: the current requirement is that you cannot have any particles larger than ten micrometers. But there are clearly higher requirements coming in the future. And we have been investing so that we will not only be competitive at this point in time, but also in the future.

Walter Rossi
39:50 - 40:09

All right. Um, two quick ones. Um, would you expect that the existing customers will place new reactor orders after they have completed the acceptances, or only after they have been using the first machine in mass production?

Juha Kokkonen
40:15 - 41:33

I, I don't know precisely. I think that what will drive this one will be the capacity demand and how much capacity they will need and when. And so more capacity will be required in addition to the first reactor. So I think that will be the main driver for the timing of ordering new reactors. Of course, then the customers are playing risk games, questioning whether they are ready to place orders once they have essentially accepted that one. So I think that from our perspective, the key thing has been ensuring that for the first customer, the reaction to and delivery according to customer requirements have been accepted. So I think from that perspective, they should be ready to move forward from Canatu's perspective. I think that then the next risk level there from their side is what they are. Of course, they need to make sure that when they are adding the full pellicle that has the coating and certain other kinds of steps there further, those are under their control, but that's very much dependent on the decision-making process there. But I think that the main driver for new reactors will be the capacity.

Walter Rossi
41:35 - 41:46

All right. Thank you. Final one from Mikko, actually. Um, how much was the revenue recognition? Uh, from the first reactor sale in H1 this year?

Mikko Vesterinen
41:47 - 42:12

Uh, we haven't disclosed that. So because we try to preserve the pricing information. And that's quite sensitive from that perspective. It had like um. Let's say it was an important element for the first part of the revenue. But how much of it was from the €7.3 million, that we will not disclose.

Walter Rossi
42:13 - 42:38

Final one from Mikko, actually. Thank you very much for your answers. Hi. This is from India, first about your sales pipeline. Can you say anything about that? How many reactors are we talking about? If you say that your existing customers might order more and you have some new discussions going on. Are there any specific numbers regarding the reactors that could be delivered in the coming years?

Juha Kokkonen
42:40 - 44:06

I think that, first of all, when we look at our addressable market, what we have said is that if we look at the. EUV pellicle products. We are saying that the addressable market in 2030 with scenario A includes logic and focuses only on the high power scanners for that market opportunity. There is €1 billion. When we are talking about the wider coverage with the conventional equipment, as well as covering more about memory markets, We are talking about a €2 billion market for our current business model. That is reactor sales there. We have been communicating that the addressable market opportunity is in the ballpark of a couple of hundred million. So I think that we have not been disclosing. We have not been disclosing the number of reactors there. But if you think about these couple of hundreds of millions and you somehow know what our reactor price is based on our first two reactor prices, you will understand that we are not talking about ones or twos, but rather about tens.

Walter Rossi
44:08 - 44:23

And if you think about your manufacturing capabilities, if we assume that you get a couple more reactors, how many reactors can you have under production? Or you can build at the same time in your current factories. Of course, you're now expanding.

Juha Kokkonen
44:23 - 44:35

Expanding in our current factory. At the same time, we can build two, but now we have this new factory, and this is not an issue. You should not be worried about this one. We will have the capacity to build reactors.

Walter Rossi
44:36 - 44:50

All right. And then about the investment in that laser tech machine, does it imply that you are taking steps towards manufacturing the whole pellicles inside your facilities?

Juha Kokkonen
44:51 - 45:36

With these new requirements coming to the industry, you must always reduce the size of the particles. So the current requirement from ASML is that there can be no particles larger than ten micrometers. But we already know that there will be further requirements. And we need to have machines even for our own reactor development because this reactor cannot produce those particles either. So for our future reactor development, we need to ensure that reactors do not generate those particles. And we need to have the kind of equipment with which we can measure that effectively.

Walter Rossi
45:37 - 45:58

And if you still think about the pellicle market for those higher watt machines, is it now the industry standard that CNT will be the material from which the pellicles are made, or is there any competitive material that could still compete with your CNT?

Juha Kokkonen
45:58 - 46:38

Yeah, I think that if you look at ASML and even public roadmaps, it is mentioned clearly that there's a transition point at 600W, where advanced material for CNT is the focus, and we are not aware of any other competing material to be part of this game during this time frame. Like new, new competing material, of course, we are competing with metal silicide. That is the existing solution there.

Walter Rossi
46:38 - 47:04

Yeah. And last question from me: you have mentioned now that the market is growing or moving forward slower than you were expecting one year ago. So is there any, uh, educated guess as to how much the market delay is right now compared to your previous expectations? Is it like one year, or?

Juha Kokkonen
47:05 - 47:29

I think that you get a very clear answer if you look at ASML's roadmap at the end of '23. And if you look at the roadmap now, like the end of the first half of 2025 and you compare them, it's more than 12 months.

Walter Rossi
47:30 - 47:31

All right. Thank you very much.

Matt DNB Carnegie
47:35 - 47:59

Uh good afternoon. It's Matt from DNB Carnegie Investment Bank AB. A couple of questions. Um, first of all, um, when you talked about your competitiveness and you said that you have not lost any deals, does it mean that some deals have already been awarded? Or does it mean that you are still in the game and maybe some others have kind of been washed out?

Juha Kokkonen
48:06 - 48:45

That's a difficult question to answer without disclosing anything there. So first of all, clearly we have not lost any gains. Then you can think about what I could say is that there are some new prospective cases where, let's say. With new prospective cases, we don't necessarily see competition from companies C and D at all.

Matt DNB Carnegie
48:49 - 49:07

Right. So, so far you haven't closed any new deals, but you think that your chances of getting those new deals that are in the pipeline are better because the competition is either smaller or lacking altogether. Is that correct?

Juha Kokkonen
49:07 - 49:33

Yeah, we do see that. How do we see competition, such as Lintec and Mitsui? How do we see them today compared to the situation a year ago? How did we see them like one year ago? We do see, based on the kind of interaction and projects with the customer, that our competitive position is better compared to the situation a year ago.

Matt DNB Carnegie
49:35 - 50:17

All right. Fair enough. Um, then to perhaps simpler questions, um, you now have the two reactors in different phases of acceptance from your customers. Um, of course, we would like to assume that the second time would always be quicker. So what kind of speed-ups could we be talking about for the second reactor acceptance phases? And, uh, do you see that it's developing as you, um, previously planned? And, uh, how is it kind of going forward?

Juha Kokkonen
50:17 - 51:38

Yeah, I think that we do see, actually, that the second reactor deliveries can be significantly faster for a couple of reasons. Firstly, there have been requirements from ASML. So we had to deliver improvements to our product and develop our product while we were manufacturing them. So that was one aspect. The second thing is that we had to make customer-specific implementations so that they are, for example, completely interoperable with the IT system. So their robotic systems and automation systems were one-time developments that we have completed right now. So, of course, while we have been working on these reactors and manufacturing them, we have also learned how to do it. Our supply chain has been learning how to do it. So we do believe that, and also our customers do as well, because there have been, for example, safety elements as we are bringing new ingredients to the factories; those have now been reviewed, and they have been accepted and so on. So we do expect that the next deliveries will be significantly faster.

Matt DNB Carnegie
51:39 - 52:03

Right. And then if we talk about a concrete timeline, we could roughly say that the first reactor took maybe 12 months to get the acceptances to the stage where you are now. So would it be that the next one will be done in six months? Is it possible, or is the 12 months a realistic scenario?

Juha Kokkonen
52:05 - 52:30

First of all, I think that we have been very open about this, for example, with the first reactor shipment we did in August last year. It was approved at the beginning of July. So we are talking about roughly ten months to be precise. I think we have been giving these timelines here. So yes, I do expect that the second reactor approvals will be significantly faster.

Matt DNB Carnegie
52:32 - 52:35

And significantly, meaning maybe half the time.

Juha Kokkonen
52:35 - 52:36

Could it be?

Matt DNB Carnegie
52:36 - 53:03

So, would it be that the next one would be done in six months? Good. Um. Then, regarding the automotive business, where you gained a new order and showed quite good revenue in the first half. Is that the revenue run rate that we should expect for the second half as well? Or do you see that there would be an acceleration also in automotive revenue in the second half?

Mikko Vesterinen
53:07 - 53:34

I think we have quite a good pace for the second half. Uh, building on this, exactly the same contract that we were discussing now involves development with Denso. And then we have, like, things that are in the pipeline, which we hope to close and start delivering. So. So it will depend on those. But I would say that the base is good for the second half.

Matt DNB Carnegie
53:35 - 53:47

So if I understand correctly, you would at least expect the same revenue in the second half in automotive. And maybe, if all things go well, there will be an increase in that revenue.

Mikko Vesterinen
53:48 - 54:04

Well, maybe I didn't confirm your expectations, but like I said, the base is good, and there are things in the pipeline which we hope to still close before the year-end.

Matt DNB Carnegie
54:05 - 54:28

So would it be that the next one would be done in six months? So would it be that the next one would be done in six months? Um, then we didn't talk that much about your second factory ramp-up. You said that it's going as planned. So when should we expect that? It's basically in a position to start taking new orders or begin delivering and building the new reactors at your site?

Juha Kokkonen
54:30 - 54:56

We haven't, like, completely disclosed that information. Information yet. We have started to build that factory and develop the basic capabilities for this facility. I think that we will most likely address this in the CMD or in the near future. Tell me more about that one. So, what is the timeline, and what kind of investments will we make there? So, but I don't want to do it right now.

Matt DNB Carnegie
54:56 - 55:37

All right. Fair enough. And then finally, um, it's a bit difficult to understand how your costs develop during the year because you have been hiring more people. You are making more investments in various areas of your production and product development. So what would be a good guess for your, uh, cost rate for the second half if we talk about fixed costs, of course. In comparison with the first half. So how much of an increase do you see in your fixed costs for the second half?

Mikko Vesterinen
55:38 - 56:30

I would say that if you look at the headcount development, that gives a quite good proxy of how this fixed cost base will grow. So, now at the end of the first half, I think we had something like 148 people. And it was roughly 20 more than a year ago. So, so that kind of like a. You can approximate from there how it will grow, but it will not be an exact guidance for our cost base for the full year. But, it's obvious that we are investing in future growth and in the teams for these reasons. So, it's also on the growth trajectory. Trajectory.

Matt DNB Carnegie
56:31 - 56:48

All right. And is it correct to assume that the headcount will continue to increase towards the end of the year, or will the end-of-first-half number be the one you maintain at the end of the year? So, how much of an increase do we see?

Mikko Vesterinen
56:48 - 57:18

That's a good question. Uh, of course, six months is a reasonably short time in this recruitment. Um, but I would expect that the trend, of course, continues to grow, and we continue on the growing trend. We will see then when we reach the full year. But I expect some growth there.

Matt DNB Carnegie
57:19 - 57:22

All right. Fair enough. Thank you. That's all from me.

Marie Makkonen
57:25 - 57:41

Thank you very much. Good questions. Let's take a couple of questions from the chat as well. So, first question to Nedal. Um, concerning medical diagnostics, why isn't tumor DNA detection one of your focus areas in addition to hormones and infectious diseases?

Nedal Safwat
57:42 - 58:36

Very good question. So, you know, oncology or oncology diagnostics are, um, quite a long journey, and the cost of development is quite high. And that's why we decided to focus on early stages and also understand how our technology has a strong potential for oncology or tumor detection. But to put it in our roadmap, we really have to make sure that the cost path, the development timeline, and the regulatory registration are acceptable and within reason. And that's why we really kind of put it in the background. We really kind of put it in the background. We are understanding the potential of the technology, but wanted to make sure that we don't rush to the forefront with a significant cost and regulatory registry requirement.

Marie Makkonen
58:38 - 58:55

Thank you. Um, then a question about the industry's adaptation to high power. So what drives that process, and what could change the situation for the better? Why is it delayed in your view?

Juha Kokkonen
58:57 - 60:08

The key driver, first of all, the key enabler is the ASML 600 watt scanner. Timing of that one. That's kind of the key thing. And there are both low and high energy. Uh, then the next thing there is how fast that is deployed by the key foundries and creates a demand. What is, of course, very positive here is what we discussed; the growth of artificial intelligence is consistently very, very high. That is pushing the envelope on these advanced chips for better delivery. So faster, more cost-efficient, as well as less power-consuming chips. So, that is the key driver there. So I think that, from my perspective, the key is that ASML will deliver in time. And there's a high demand for advanced chips. That seems to be the case.

Marie Makkonen
60:12 - 60:36

Then, um, earlier you mentioned that there might be a possibility that Canatu Plc CNT pellicles would also be used in 500-watt scanners. But you also mentioned that it will improve productivity. Uh, but you also doubted that the CNT pellicles would be used because of the high price. So, has something changed?

Juha Kokkonen
60:39 - 61:32

No, I think that, uh, I don't remember what I have communicated regarding the price there. So, because pricing is not determined by Canatu's side, I think that if I'm first commenting from the cost perspective. So this metal silicide process has over 100 process steps. It's very costly compared to the CAD process. Then it is the question that, of course, if you are delivering a higher productivity scanner, it can be priced even higher. And that is, of course, the question and decision of our customers on how they are priced. What was the first part of the question? Sorry, I forgot that one.

Marie Makkonen
61:33 - 61:39

Do you still believe that CNT pellicles will be used also with 500 watt systems?

Juha Kokkonen
61:40 - 61:59

So the, the. Yes, what we do see on the market is that there are plans to use CNT pellicles with two nanometer nodes as well as with 500 watt systems. So once for that one is that. Yes, I do believe.

Marie Makkonen
62:03 - 62:30

Then ASML has stated in the quarterly reports that the advanced scanner market won't grow in 2026. How does Canatu Plc see the future since the high power scanner market is the main business for the company? You have quite high revenue expectations for 2027. Are you still relying on this expectation or target?

Juha Kokkonen
62:32 - 63:40

And there's a high demand for advanced chips. So, like I said, we still have the same target. So, €100 million revenue for 2027. What we mentioned there is that there's now a materially increased risk for the delay of that revenue. And from this side, we mentioned what the key assumptions are that need to happen. Let's say the three key elements are there. Firstly, that our competitive position remains strong like it is today. Secondly, this ASML deployment and development timeline will proceed according to current plans. And then thirdly, that CNT pellicle will be the key solution for 600 watt systems. So those are the three key assumptions that are based on these events occurring during the period of 2026 and 2027.

Marie Makkonen
63:42 - 63:47

Thank you. And do we have any further questions from the audience here? Yes, please. Walter.

Walter Rossi
63:50 - 64:17

Hi. Walter Rossi from the Bank. One more question related to the recurring revenues. You've said previously that those will be significant compared to reactor sales. To better understand that statement. Is 30% of the reactor price, you know, in terms of recurring revenue, significant for you on an annual sales basis? Is that significant?

Juha Kokkonen
64:18 - 65:19

So, first of all, um. From the total revenue perspective, as we continue, the share of recurring revenue will increase. We have an installed base of Canatu Plc contributors. The share of the recurring revenue will increase there. So that's understandable. So in the coming years, reactor sales are expected to be larger than the recurring revenue part. And then over time it will shift more towards recurring revenue than reactor sales. What is significant there? I don't want to give the exact answer, but I think that it is significantly comparable to the reactor prices. So it's not of a smaller magnitude, but it is significant in that sense.

Walter Rossi
65:22 - 65:23

All right. Thank you.

Marie Makkonen
65:24 - 65:28

And maybe a final question from the audience.

Emily DNB Carnegie
65:28 - 65:49

Yes. Thank you. Emily from DNB Carnegie Investment Bank AB. One clarifying question about the reactor and the product that is produced with the already site-accepted reactor. So is the situation now that the customer is producing a type of proof of concept or product, which their customer then has to accept?

Juha Kokkonen
65:50 - 65:50

Correct.

Emily DNB Carnegie
65:50 - 66:01

And when that kind of proof of concept product has been accepted, if you sell more reactors to that customer, they don't have to do this kind of product proofing anymore.

Juha Kokkonen
66:01 - 66:07

If they are delivering the same kind of product. That's correct.

Emily DNB Carnegie
66:07 - 66:16

One clarifying question on the reactor and the product that is produced with the already site-accepted reactor. So now you could ramp up very quickly. The consumable sales. Correct. One clarifying question on the reactor and the product that is produced with the already site accepted reactor. Correct. Okay, great. One clarifying question on the reactor and the product that is produced with the already site-accepted reactor.

Marie Makkonen
66:20 - 66:21

That's all. One clarifying question on the reactor and the product that is produced with the already site accepted reactor.

Juha Kokkonen
66:21 - 67:06

Thank you. I will state a kind of thank you for your interest here. And we will see you hopefully on March 3rd when we are going to announce our full year 2025 results. And the second highlight I'm discussing here is our Capital Markets day. We have planned for this to happen in week 13 next year, where we would like to then open more about recent developments as well as certain strategic choices. Thank you for attending this one, and thank you for the very active questions and discussion.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…